← Russell 3000 cross-section

BMRN BIOMARIN PHARMACEUTICAL INC

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$12.6bn
Revenue TTM
$3.4bn
Net income TTM
$73m
Free cash flow
$738m
Composite score
42.8
Sector rank
#614

Valuation

P / E
172.6
EV / EBITDA
50.5
EV / sales
4.5
FCF yield
5.86%
Earnings yield vs 10-yr
-4.15pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
2.1%
EBITDA margin
8.9%
ROE
1.1%
ROIC
1.7%
Revenue growth
11.2%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

The increase in Net Product Revenues for the three and six months ended June 30, 2026 as compared to the three and six months ended June 30, 2025 was primarily attributed to the following: • GALAFOLD and POMBILITI + OPFOLDA: revenues from commercial products acquired on April 27, 2026; • VOXZOGO: higher sales volume from new patients initiating therapy across all regions; and • PALYNZIQ: higher sales volume from new patients initiating therapy, primarily in the U.S. These increases were partially offset by the following: Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued) (In millions of U.S. …BIOMARIN PHARMACEUTICAL INC, 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →